The most frequent deficiencies involved protocol compliance and record-keeping. Contract research organizations (CROs) fared particularly well, with over 90% of inspections requiring no FDA follow-up. The pandemic temporarily reduced inspection volume in 2020 and led to more findings being downgraded from voluntary to no action.

Authors attribute the overall decline in violations to advances such as electronic systems, remote monitoring, updated GCP guidelines (2018), and stronger training and oversight by sponsors. However, some experts caution that the trend could also reflect fewer inspections, less experienced investigators, or reduced scrutiny rather than true improvements in compliance.

In sum: While nearly all inspections (99.7%) required no official action, the data leave open questions about inspection rigor and whether the decline truly signals stronger adherence to GCP standards.

• Form 483s (violations) decreased from 23.5% in 2017 to 10.4% in 2023, with only 0.3% requiring official action.
• Final outcomes: 81.2% no action indicated (NAI), 18.5% voluntary action indicated (VAI), 0.3% official action indicated (OAI).
• Common deficiencies: protocol adherence and record-keeping.
• CROs performed best, with >90% inspections needing no FDA action.
• Pandemic effects: inspection numbers dropped in 2020; more cases were downgraded from VAI to NAI.

Possible drivers of improvement include:

• Wider use of electronic systems and remote monitoring.
• 2018 harmonized GCP guidelines and training programs.
• Better sponsor vetting of sites after fraud cases.

Uncertainties remain:

• Lower violation rates may also reflect fewer inspections, less experienced FDA inspectors, or shifting scrutiny.
• Experts caution against assuming improved compliance without longer-term data.

Bottom line: Nearly all inspections (99.7%) required no official action, suggesting improved GCP practices, though questions remain about inspection intensity and workforce changes.

High-level overview
FY2024 saw inspection volumes rebound strongly, with a marked increase in foreign site inspections, more warning letters, and continued growth in product approvals—including biosimilars. Overall quality performance remained solid, with 93% of sites achieving NAI or VAI, though risks were concentrated in API suppliers to compounding pharmacies, OTC manufacturers, and ophthalmic product lines.

Here are the key takeaways and implications for pharma QA/RA teams.

Inspection and Manufacturing Site Trends

• Total sites in CDER Site Catalog: 4,619 (41% U.S., 59% foreign)
• Inspections conducted in FY2024: 989 (+27% vs. FY2023)
• Foreign inspections: 62% of total (all-time high)
• MRA partner inspections: 198 (highest ever)
• Global compliance outcomes: 93% NAI/VAI; Europe led at 98%, India trailed at 87%

Insight: The significant rise in foreign inspections, particularly in India and China, underscores the FDA’s focus on global supply chain oversight. MRA partnerships are increasingly critical to extend surveillance capacity.

Product Portfolio Highlights

• Total products in CDER catalog:
  • ANDAs: 14,168 (+4.4%)
  • NDAs: 3,625 (+0.9%)
  • BLAs: 383 (+8.2%), including 63 biosimilars (+47%)
  • Non-application NDCs: 140,119 (+6.7%)
• Overall product growth: +6.3%

Implication: Steady portfolio expansion highlights continued pressure on regulatory and quality teams to manage a growing and diverse drug landscape, particularly as biosimilars gain momentum.

Postmarket Quality Signals

• PQD reports: 16,837 (↓1.5%)
• MedWatch: 12,588 (+0.3%)
• Field Alert Reports (FARs): 3,515 (↓7.5%)
• BPDRs: 409 (+17%)
• Consumer complaints: 325 (↓18.3%)

Observation: While total PQDs declined slightly, the increase in BPDRs indicates ongoing challenges in biologics quality monitoring.

Import Alerts, Recalls, and Warning Letters

• Import alerts added: 75 (65% OTC, 25% API)
  • Largest shares: China 39%, India 13%, Europe 13%
• Recalls: 421 (lowest in five years)
  • Most common defects: microbial contamination (31%), sterility (28%), particulates (20%)
  • Top product categories: Ophthalmic (14.1%), Antibacterials, Cardiovascular, Dermatological
• Warning letters: 105 issued (5-year high)
  • Domestic: 41 (↓ from 59)
  • Foreign: 64 (↑), driven by inspection activity
  • Notably, 72% of warning letters against API suppliers were tied to sites supporting compounding pharmacies (only 18% of total API sites)

Takeaway: Enforcement actions are increasingly concentrated on high-risk segments, particularly API suppliers for compounding, and underscore the importance of proactive quality management and supply chain oversight.

API Supply Chain Concerns

A standout finding: API sites serving compounding pharmacies continue to exhibit disproportionate quality challenges. Despite representing just 18% of all API manufacturers, these sites accounted for 72% of regulatory actions, primarily located in China (51%) and India (30%).

Implication: Quality professionals in compounding and API procurement should prioritize auditing, QMS strengthening, and inspection readiness. The trend aligns with a notable uptick in sites proactively engaging with RA/QA consultants to address gaps.

Import Alerts Signal Broader Surveillance

The FDA issued import alerts to 75 sites, with 40% targeting facilities never previously inspected. OTC monograph drug manufacturers accounted for the majority (65%), while API manufacturers made up 25%. The use of Section 704(a)(4) records requests allowed the FDA to extend oversight beyond traditional inspections.

Drug Amount Reporting: Progress and Gaps

• Compliance for application products (CY2024): BLAs 71%, NDAs 65%, ANDAs 60%
• OTC monograph products: Only 37% compliant

Implication: Incomplete reporting may increasingly influence inspection targeting and risk prioritization, emphasizing the need for accurate, timely data submission.

Bottom line for pharma QA/RA teams:
FY2024 reinforces that inspection intensity, foreign site oversight, and supply chain risk management remain at the forefront. Regulatory strategies must account for rising enforcement, targeted oversight of high-risk segments, and the ongoing expansion of product portfolios, particularly biosimilars and compounding APIs.

• Inspections: 989 total (+27% vs FY2023), with 62% foreign (all-time high)
• MRA partner inspections: 198 (highest ever)
• Compliance: 93% of sites NAI/VAI; Europe led (98%), India lowest (87%)

Key Takeaway: Foreign oversight is surging—particularly India and China—while global compliance remains strong but uneven.

Product Portfolio Growth

• ANDAs: 14,168 (+4.4%)
• NDAs: 3,625 (+0.9%)
• BLAs: 383 (+8.2%), including 63 biosimilars (+47%)
• Non-application NDCs: 140,119 (+6.7%)

Key Takeaway: Expansion, especially in biosimilars, is increasing regulatory and quality management demands.

Postmarket Quality Signals

• PQDs: 16,837 (↓1.5%)
• BPDRs: 409 (+17%)
• FARs: 3,515 (↓7.5%)

Key Takeaway: Biologics deviations rising; continued vigilance needed for high-risk product lines.

Enforcement & Import Alerts

• Warning letters: 105 issued (5-year high)
  • Domestic: 41, Foreign: 64 (inspection-driven)
  • API suppliers to compounding pharmacies: 72% of actions, though only 18% of sites
• Import alerts: 75 sites added; 40% never inspected before
• Recalls: 421 (lowest in 5 years); top defect = contamination (microbial 31%, sterility 28%)

Key Takeaway: Enforcement is concentrated on high-risk supply chains, particularly compounding APIs, OTC monograph products, and ophthalmics.

Data & Reporting Insights

• Drug amount reporting improved for application products (BLAs 71%, NDAs 65%, ANDAs 60%)
• OTC monograph compliance lags at 37%
• Incomplete reporting may increasingly drive inspection targeting

Strategic Implications for QA/RA Leaders

1. Prioritize high-risk suppliers: Focus on API providers for compounding and foreign manufacturing sites.
2. Strengthen QMS and inspection readiness: Proactive audits reduce risk of 483s or warning letters.
3. Leverage regulatory intelligence: Monitor FDA enforcement trends and 704(a)(4) records requests for strategic oversight.
4. Data-driven surveillance: Ensure accurate product reporting; gaps may trigger targeted inspections.

Bottom line: FY2024 signals heightened global oversight, targeted enforcement, and supply chain focus. QA/RA teams must balance compliance, proactive risk mitigation, and portfolio growth management to stay ahead.

This article explores why warning letters are increasingly frequent and consequential, how issues escalate from Form 483 observations to public enforcement, and what recent cases reveal about shifting regulatory boundaries — particularly around wellness versus medical claims. The goal: We want you to view warning letters as a strategic resource that your quality and regulatory leaders can use to anticipate risks, avoid costly missteps, and drive your company to become the best in the world!

Why Warning Letters Matter Now More Than Ever

The FDA’s Final Wake-Up Call
A warning letter signals serious violations that demand immediate correction. Unlike the private Form 483 inspection report, a warning letter is public and carries reputational, operational, and financial consequences. If deficiencies aren’t addressed, it can trigger import bans, product seizures, injunctions, or even facility shutdowns.

Rising Frequency and Visibility
Warning letters are becoming more common. Between 2022 and 2023, the rate rose 43% — from 2.98 to 4.27 per 100 inspections. By FY2024, device-related warning letters nearly doubled year over year (47 vs. 24). Early 2025 data suggest this higher pace is continuing.

This increase reflects the FDA’s risk-based approach. Even during COVID-19 lockdowns, the agency enforced compliance through remote reviews and testing, a practice it continues to leverage. The message is clear: scrutiny has not softened.

Business and Global Fallout
The consequences extend beyond FDA oversight. Once posted publicly, a warning letter can shake investor confidence, disrupt supply chains, and stall product approvals. Regulators worldwide — from Europe to Canada — closely monitor FDA actions, meaning a single U.S. warning can ripple across multiple markets.

From Form 483 to Warning Letter: How Issues Escalate

Most warning letters are based on a Form 483 inspection finding. The difference between resolution and escalation lies in the response. Companies have 15 business days to submit corrective actions; weak or delayed responses almost guarantee escalation.

Common pitfalls include:

• Superficial root cause analysis: fixing symptoms rather than identifying underlying causes.
• Vague corrective actions: promising improvement without detailed plans, timelines, or evidence.
• Defensive tone: disputing FDA findings instead of focusing on remediation.
• Missed deadlines: failing to reply within 15 days or neglecting interim updates.

Effective responses from your organization that will make FDA smile require rigorous root cause analysis, robust CAPAs, and clear accountability. Many firms engage external experts to review draft responses — a practice increasingly encouraged by FDA.

Key Trends Shaping FDA Enforcement

1. Quality System Gaps Dominate
Quality management failures are almost always the most common citation, from weak oversight by quality units to inadequate training. These foundational screw ups often trigger broader system failures.

2. Data Integrity Under the Microscope
Once rare, data integrity violations — altered test results, missing records, weak audit trails — are now a frequent focus. With digital systems ubiquitous, validated controls and reliable audit trails are nonnegotiable.

3. Global Manufacturers Face Added Scrutiny
The share of warning letters issued to overseas facilities has soared in the last three years, with India and China in particular drawing attention. The FDA has increased oversight to address inconsistent inspection rigor abroad, putting global supply chains under tighter watch.

4. Fewer Inspections, More Targeted Enforcement
Routine FDA inspections have declined, but enforcement intensity has risen. Remote reviews and product testing now trigger many warning letters, reflecting the FDA’s more risk-driven, tech-enabled oversight model.

Case Spotlight: Wellness vs. Medical Claims

The FDA’s evolving stance is evident in its July 2025 warning to WHOOP. The company marketed a wearable feature providing daily blood pressure estimates as a wellness tool. The FDA disagreed, concluding it functioned as a medical device by implicating hypertension diagnosis.

This follows 2024 FDA actions against wearables claiming to measure blood glucose without clearance. The lesson: simply labeling a product as “wellness” no longer shields it from oversight if features cross into diagnostic territory. Companies developing digital health tools must validate claims, engage regulators early, and align with FDA expectations.

Conclusion

FDA warning letters are not just punitive measures to make companies sweat — they are windows into evolving standards, systemic risks, and regulatory priorities. By studying them, companies can identify vulnerabilities, anticipate enforcement, and strengthen their quality culture.

An FDA warning letter not just a formal notice — it’s a public declaration that a company’s quality system has failed to meet critical standards. But beyond the reputational sting, these letters offer valuable intelligence. Each one reveals patterns, systemic weaknesses, and evolving enforcement priorities that medical device manufacturers can analyze to strengthen compliance and build resilience.

This first part of a two-part series explores why warning letters are increasingly frequent and consequential, how issues escalate from Form 483 observations to public enforcement, and what recent cases reveal about shifting regulatory boundaries — particularly around wellness versus medical claims. The goal: reframe FDA warning letters as a strategic resource that quality and regulatory leaders can use to anticipate risks, avoid costly missteps, and drive operational excellence.

Why Warning Letters Matter Now More Than Ever

The FDA’s Final Wake-Up Call
A warning letter signals serious violations that demand immediate correction. Unlike the private Form 483 inspection report, a warning letter is public and carries reputational, operational, and financial consequences. If deficiencies aren’t addressed, it can trigger import bans, product seizures, injunctions, or even facility shutdowns.

Rising Frequency and Visibility
Warning letters are becoming more common. Between 2022 and 2023, the rate rose 43% — from 2.98 to 4.27 per 100 inspections. By FY2024, device-related warning letters nearly doubled year over year (47 vs. 24). Early 2025 data suggest this higher pace is continuing.

This increase reflects the FDA’s risk-based approach. Even during COVID-19 lockdowns, the agency enforced compliance through remote reviews and testing, a practice it continues to leverage. The message is clear: scrutiny has not softened.

Business and Global Fallout
The consequences extend beyond FDA oversight. Once posted publicly, a warning letter can shake investor confidence, disrupt supply chains, and stall product approvals. Regulators worldwide — from Europe to Canada — closely monitor FDA actions, meaning a single U.S. warning can ripple across multiple markets.

From Form 483 to Warning Letter: How Issues Escalate

Most warning letters trace back to a Form 483 inspection finding. The difference between resolution and escalation lies in the response. Companies have 15 business days to submit corrective actions; weak or delayed responses almost guarantee escalation.

Common pitfalls include:

• Superficial root cause analysis: fixing symptoms rather than identifying underlying causes.
• Vague corrective actions: promising improvement without detailed plans, timelines, or evidence.
• Defensive tone: disputing FDA findings instead of focusing on remediation.
• Missed deadlines: failing to reply within 15 days or neglecting interim updates.

Effective responses require rigorous root cause analysis, robust CAPAs, and clear accountability. Many firms engage external experts to review draft responses — a practice increasingly encouraged by FDA.

Key Trends Shaping FDA Enforcement

1. Quality System Gaps Dominate
Quality management failures remain the most common citation, from weak oversight by quality units to inadequate training. These foundational lapses often trigger broader system failures.

2. Data Integrity Under the Microscope
Once rare, data integrity violations — altered test results, missing records, weak audit trails — are now a frequent focus. With digital systems ubiquitous, validated controls and reliable audit trails are nonnegotiable.

3. Global Manufacturers Face Added Scrutiny
The share of warning letters issued to overseas facilities has climbed, with India and China in particular drawing attention. The FDA has increased oversight to address inconsistent inspection rigor abroad, putting global supply chains under tighter watch.

4. Fewer Inspections, More Targeted Enforcement
Routine inspections have declined, but enforcement intensity has risen. Remote reviews and product testing now trigger many warning letters, reflecting the FDA’s more risk-driven, tech-enabled oversight model.

Case Spotlight: Wellness vs. Medical Claims

The FDA’s evolving stance is evident in its July 2025 warning to WHOOP. The company marketed a wearable feature providing daily blood pressure estimates as a wellness tool. The FDA disagreed, concluding it functioned as a medical device by implicating hypertension diagnosis.

This follows 2024 FDA actions against wearables claiming to measure blood glucose without clearance. The lesson: simply labeling a product as “wellness” no longer shields it from oversight if features cross into diagnostic territory. Companies developing digital health tools must validate claims, engage regulators early, and align with FDA expectations.

Conclusion

FDA warning letters are not just punitive measures — they are windows into evolving standards, systemic risks, and regulatory priorities. By studying them, companies can identify vulnerabilities, anticipate enforcement, and strengthen their quality culture.

In a future article, we’ll shift from insight to action: practical steps for building resilient quality management systems, embedding regulatory intelligence into decision-making, and using enforcement data to gain competitive advantage.

As of July 31, 2025, the agency had received 605 adverse event reports for compounded semaglutide and 545 reports for compounded tirzepatide, the FDA said. Regulators emphasized that the true number is likely higher, since many compounding pharmacies are not required to report side effects.

Dosing Errors a Major Concern

A significant share of reports stemmed from dosing mistakes with compounded semaglutide. Unlike brand-name GLP-1 drugs, which are packaged in prefilled pens that allow patients to simply “dial up” the prescribed dose, compounded products are often supplied in vials and drawn up with syringes.

“When patients have to fill their own syringes, there are more opportunities for dosing errors,” said Melanie Jay, MD, professor at NYU and director of the NYU Langone Comprehensive Program on Obesity Research.

In some cases, patients or providers administered incorrect amounts, or prescribed doses higher than those in FDA-approved versions. Reported side effects included nausea, vomiting, diarrhea, abdominal pain, constipation, and injection-site reactions. Several patients required medical treatment.

How Widespread Are the Risks?

The FDA has not disclosed how many people nationwide are taking compounded GLP-1s, making it difficult to assess the overall rate of adverse events.

“It’s really hard to get a handle on the actual number of prescriptions and adverse events,” said Jody Dushay, MD, an endocrinologist at Harvard Medical School and Beth Israel Deaconess Medical Center. “If I had to guess, this is the tip of the iceberg — not only in terms of adverse events, but also in terms of patients who aren’t benefiting from these medications.”

Adverse events may be underreported because patients often don’t inform prescribers or pharmacies when problems arise, Dushay added. Some sellers may also fail to notify the FDA.

Not Always the Drug Itself

The Alliance for Pharmacy Compounding (APC) cautioned that the FDA’s tally doesn’t prove compounded GLP-1s directly caused these issues. Some patients may have taken counterfeit or fraudulent products from unlicensed sources, rather than medicines prepared by legitimate compounding pharmacies.

Compounding pharmacies, licensed by state boards, are permitted to create customized medicines using the same active ingredients in FDA-approved drugs — often for patients who need nonstandard doses or when commercial products are unavailable, as was the case during past shortages of Wegovy and Ozempic.

The big issue is desiccated thyroid extracts — made from dried pig thyroid glands — which have been used for more than a century to treat hypothyroidism. While most patients today rely on FDA-approved synthetic replacements, some still use the animal-derived versions. The FDA, citing more than 500 adverse event reports between 1968 and February 2025 (with a sharp uptick around 2019–2020), told firms it would no longer tolerate sales of unapproved versions.

“FDA is committed to pursuing the first-ever approval of desiccated thyroid extract, pending ongoing clinical trials,” Commissioner Marty Makary wrote on X. He added that the agency would allow a transition period of about 12 months to shift patients to approved drugs.

The announcement set off a storm on social media. Wellness influencers aligned with Kennedy accused the FDA of bowing to industry pressure. Brigham Buhler, owner of ReviveRX and a Kennedy ally, claimed the decision benefits AbbVie — maker of synthetic thyroid treatments and a company currently running its own trials. “Is this the FDA working for Pharma again… to create another monopoly so they can raise prices like Martin Shkreli?” he said.

AbbVie, for its part, pledged to work with the FDA to ensure uninterrupted access and stressed its commitment to patients through ongoing trials. The FDA declined an interview request.

Why Is This Important?

For patients, the fight is not academic. Hypothyroidism treatments must be finely calibrated; too little leaves patients exhausted, while too much can cause dangerous side effects. Advocates like Tenille Davis of the Alliance for Pharmacy Compounding argue that a subset of patients simply don’t respond well to synthetic hormones. “Their blood panels may look fine, but they still feel awful — until they switch to the natural extracts,” Davis said.

Though these patients may represent a minority, she added, they are far from negligible given the widespread prevalence of hypothyroidism. “It’s happened enough times that these patients aren’t crazy,” Davis said.

The commissioner’s National Priority Voucher or CNPV program gathers drug experts from various FDA offices for team-based reviews, rather than the traditional drug review system where the NDA was sent to several offices across the country.

FDA will give a limited quantity of vouchers in the next year to firms that are aligned with FDA’s priorities. The new voucher program intends to speed up the NDA process, but still maintain the agency’s focus on safe, effective, and quality drugs. The National Priority Review Plan will allow firms to submit most NDAs before they complete clinical trials, which will reduce inefficiencies and delays.

FDA Commissioner Marty Makary also noted this week that he wants FDA to become nimbler int he next five years to accelerate the development of medical innovation. As part of that process, Makary says FDA is looking at new pilots and programs. He noted that he wants a universal influenza vaccine that would be effective for many strains of bird flue and wouldn’t require yearly immunization.

He also noted that he wants to see better treatments for type 1 diabetes and better cell and gene therapies, especially for the rarest diseases.

Makary said that FDA should ask itself why it takes a decade for new pharmaceuticals to hit the market. He noted that barriers to getting new drugs to patients is often because of the onerous drug approval process, and that FDA needs to question long-held assumptions about legacy systems it uses to put products on the market. “We need to be willing to learn from data that isn’t only from randomized clinical trials. We can learn from data in the real world, and we can learn from synthetic controls available today in national electronic health records.”

The caption quoted Eckert, ‘This isn’t about a pill at all, it’s about dismantling a double standard that never should have existed.’ The warning letter said the post was entirely promotional and didn’t include information about risks, full indication, or limitations.

We see this social media-related warning letter as another sign that FDA will focus more on drug promotions and advertising. There will likely be more warning letters targeting social media promotion and advertising that are sent to executives or personal social media accounts.

Addyi is the first medication approved by FDA to treat premenopausal women who have generalized, acquired hypoactive sexual desire disorder. However, it should only be used in limited populations and has many safety warnings required. One of them is a boxed warning for low blood pressure and fainting, especially when taken with certain medications or alcohol.

The Instagram post was shared on the CEO’s personal Instagram account. It included content from an article in People Magazine and the CEO’s statement about the article. FDA made it clear that it thinks a screenshot and user-generated content is one post. This is important to understand the context for this letter and understanding how the agency is thinking about these common types of social media posts.

Fair Balance

On the surface, the Instagram post has good intentions: The aim is to talk about female sexual dysfunction and encourage conversation about this seldom-discussed issue. The CEO’s social media post tells a personal story about a woman living with the condition. However, FDA requires any communication that states the name of a drug and discusses how it’s used must follow promotional requirements issued by the agency. FDA regulations mandate there be fair balance between information about the benefits and risks of the pharmaceutical.

FDA notes in the warning letter that there isn’t any fair balance at all; nothing is mentioned about the drug’s risks or indications. If Addyi didn’t have a boxed warning, the lack of safety language may have led to a less serious FDA response.

FDA took the CEO to task for promoting the drug generally for the sexual health of women, without adding usage and safety information. It left the impression that Addyi is safe and effective for a larger group of people than the agency has approved.

Limitations Of Use

FDA notes that per the indications of use section of the product labeling, Addyi is for treating premenopausal women with hypoactive sexual desire disorder. The symptoms are low sexual desire that causes interpersonal difficulty and stress. HSDD isn’t due to a psychiatric or medical condition, problems with the partner, or effect of another drug. Addyi isn’t for postmenopausal women, men, or to boost sexual performance.

The post doesn’t discuss the limitations of use for the drug, and more subtlely, the post makes a claim that it’s the sex pill for women, suggesting that Addyi boosts sexual performance and can be used by women generally.

FDA’s concern with the advertising is that once the drug and use are mentioned, FDA’s promotional rules are in effect. The content must state the drug’s approved uses and not mislead readers. In this case, the agency argues that the Instagram post gives the impression that the drug can be used by all women who want sexual improvements, regardless of their age or medical conditions. The reality is different – FDA has approved Addyi only for a certain patient population.

FDA stated at the end of the warning letter that the company must provide a detailed plan for providing truthful, non-misleading, and complete communciations to the public about the issues raised in the letter.

Limited information is available about the latest 483. It is believed there were possible procedural and documentation lapses that require correction actions.